tetano
Editor, Senior Moderator
Vaccine. 2020 Feb 24. pii: S0264-410X(20)30228-0. doi: 10.1016/j.vaccine.2020.02.031. [Epub ahead of print] [h=1]The impact of new universal child influenza programs in Australia: Vaccine coverage, effectiveness and disease epidemiology in hospitalised children in 2018.[/h]
Blyth CC[SUP]1[/SUP], Cheng AC[SUP]2[/SUP], Crawford NW[SUP]3[/SUP], Clark JE[SUP]4[/SUP], Buttery JP[SUP]5[/SUP], Marshall HS[SUP]6[/SUP], Francis JR[SUP]7[/SUP], McRae J[SUP]8[/SUP], Kotsimbos T[SUP]9[/SUP], Kelly PM[SUP]10[/SUP], Macartney KK[SUP]11[/SUP]; Paediatric Active Enhanced Disease Surveillance (PAEDS), Influenza Complications Alert Network (FluCAN) Collaboration.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] New jurisdictionally-based vaccination programs were established providing free quadrivalent influenza vaccine (QIV) for preschool Australian children in 2018. This was in addition to the National Immunisation Program (NIP) funded QIV for Indigenous children and children with comorbid medical conditions. We assessed the impact of this policy change on influenza disease burden and vaccine coverage, as well as report on 2018 vaccine effectiveness in a hospital-based surveillance system.
[h=4]METHODS:[/h] Subjects were recruited prospectively from twelve PAEDS-FluCAN sentinel hospital sites (April until October 2018). Children aged ≤16 years hospitalised with an acute respiratory illness (ARI) and laboratory-confirmed influenza were considered cases. Hospitalised children with ARI who tested negative for influenza were considered controls. VE estimates were calculated from the adjusted odds ratio of vaccination in cases and controls.
[h=4]RESULTS:[/h] A total of 458 children were hospitalised with influenza: 31.7% were <2 years, 5.0% were Indigenous, and 40.6% had medical comorbidities predisposing to severe influenza. Influenza A was detected in 90.6% of children (A/H1N1: 38.0%; A/H3N2: 3.1%; A/unsubtyped 48.6%). The median length of stay was 2 days (IQR: 1,3) and 8.1% were admitted to ICU. Oseltamivir use was infrequent (16.6%). Two in-hospital deaths occurred (0.45%). 12.0% of influenza cases were vaccinated compared with 36.0% of test-negative controls. Vaccine effectiveness of QIV for preventing influenza hospitalisation was estimated at 78.8% (95%CI: 66.9; 86.4).
[h=4]CONCLUSIONS:[/h] Compared with 2017 (n = 1268 cases), a significant reduction in severe influenza was observed in Australian children, possibly contributed to by improved vaccine coverage and high vaccine effectiveness. Despite introduction of jurisdictionally-funded preschool programs and NIP-funded vaccine for children with risk factors for severe disease, improved coverage is required to ensure adequate protection against paediatric influenza morbidity and mortality.
Copyright ? 2020 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Children; Hospitalization; Influenza; Vaccination; Vaccine effectiveness
PMID: 32107062 DOI: 10.1016/j.vaccine.2020.02.031
Blyth CC[SUP]1[/SUP], Cheng AC[SUP]2[/SUP], Crawford NW[SUP]3[/SUP], Clark JE[SUP]4[/SUP], Buttery JP[SUP]5[/SUP], Marshall HS[SUP]6[/SUP], Francis JR[SUP]7[/SUP], McRae J[SUP]8[/SUP], Kotsimbos T[SUP]9[/SUP], Kelly PM[SUP]10[/SUP], Macartney KK[SUP]11[/SUP]; Paediatric Active Enhanced Disease Surveillance (PAEDS), Influenza Complications Alert Network (FluCAN) Collaboration.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] New jurisdictionally-based vaccination programs were established providing free quadrivalent influenza vaccine (QIV) for preschool Australian children in 2018. This was in addition to the National Immunisation Program (NIP) funded QIV for Indigenous children and children with comorbid medical conditions. We assessed the impact of this policy change on influenza disease burden and vaccine coverage, as well as report on 2018 vaccine effectiveness in a hospital-based surveillance system.
[h=4]METHODS:[/h] Subjects were recruited prospectively from twelve PAEDS-FluCAN sentinel hospital sites (April until October 2018). Children aged ≤16 years hospitalised with an acute respiratory illness (ARI) and laboratory-confirmed influenza were considered cases. Hospitalised children with ARI who tested negative for influenza were considered controls. VE estimates were calculated from the adjusted odds ratio of vaccination in cases and controls.
[h=4]RESULTS:[/h] A total of 458 children were hospitalised with influenza: 31.7% were <2 years, 5.0% were Indigenous, and 40.6% had medical comorbidities predisposing to severe influenza. Influenza A was detected in 90.6% of children (A/H1N1: 38.0%; A/H3N2: 3.1%; A/unsubtyped 48.6%). The median length of stay was 2 days (IQR: 1,3) and 8.1% were admitted to ICU. Oseltamivir use was infrequent (16.6%). Two in-hospital deaths occurred (0.45%). 12.0% of influenza cases were vaccinated compared with 36.0% of test-negative controls. Vaccine effectiveness of QIV for preventing influenza hospitalisation was estimated at 78.8% (95%CI: 66.9; 86.4).
[h=4]CONCLUSIONS:[/h] Compared with 2017 (n = 1268 cases), a significant reduction in severe influenza was observed in Australian children, possibly contributed to by improved vaccine coverage and high vaccine effectiveness. Despite introduction of jurisdictionally-funded preschool programs and NIP-funded vaccine for children with risk factors for severe disease, improved coverage is required to ensure adequate protection against paediatric influenza morbidity and mortality.
Copyright ? 2020 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Children; Hospitalization; Influenza; Vaccination; Vaccine effectiveness
PMID: 32107062 DOI: 10.1016/j.vaccine.2020.02.031